Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AT

WKN: A41X00 | ISIN: US03835L7029 | Ticker:
NASDAQ
17.11.26 | 21:54
0,460 US-Dollar
-0,20 % -0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APTEVO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APTEVO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APTEVO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAptevo reports Q3 results, mipletamig AML trial data5
MoAptevo Therapeutics reports Q3 results4
MoAptevo Therapeutics legt Q3-Zahlen vor und meldet Fortschritte bei AML-Studie zu Mipletamig1
MoAptevo Therapeutics: Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results269Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy advances to potentially...
► Artikel lesen
MoAptevo Therapeutics Inc. - 10-Q, Quarterly Report1
APTEVO THERAPEUTICS Aktie jetzt für 0€ handeln
MoAptevo Therapeutics Inc. - 8-K, Current Report1
DoAptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds352SEATTLE, WA / ACCESS Newswire / November 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology...
► Artikel lesen
11.11.Aptevo Therapeutics announces exercise of existing warrants for $3M gross proceeds2
11.11.Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds301SEATTLE, WA / ACCESS Newswire / November 11, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology...
► Artikel lesen
09.11.Aptevo Therapeutics präsentiert präklinische Daten zu Krebsimmuntherapien7
09.11.Aptevo Therapeutics: Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors265In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsPreclinical work also...
► Artikel lesen
09.11.Aptevo Therapeutics Inc. - 8-K, Current Report3
05.11.Aptevo Therapeutics: Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML394Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 developmentSubstantial...
► Artikel lesen
30.10.Aptevo Therapeutics Inc. - 8-K, Current Report1
26.10.Aptevo Therapeutics: Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant333Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing clinical...
► Artikel lesen
23.10.Aptevo Therapeutics Inc. - 8-K, Current Report1
14.10.Aptevo Therapeutics Inc. - 8-K, Current Report2
14.10.Aptevo Therapeutics: Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting400Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics...
► Artikel lesen
02.10.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3-4.282The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK...
► Artikel lesen
24.09.Aptevo advances trispecific cancer therapy manufacturing4
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1